Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

22 sept. 2025 06h15 HE | Source: Alvotech

Evrópska lyfjastofnunin mælir með útgáfu markaðsleyfis fyrir AVT03, fyrirhugaða hliðstæðu Alvotech við líftæknilyfin Prolia og Xgeva

Alvotech (NASDAQ: ALVO) tilkynnti í dag að mannalyfjanefnd (CHMP) Lyfjastofnunar Evrópu (EMA) hafi mælt með því að veita markaðsleyfi fyrir AVT03, fyrirhugaða hliðstæðu Alvotech við líftæknilyfin...
22 sept. 2025 06h15 HE | Source: Alvotech

European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech’s Proposed Biosimilar to Prolia® and Xgeva®

REYKJAVIK, ICELAND (September 22, 2024) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today...
04 sept. 2025 08h50 HE | Source: Bonafide® Health, LLC

Bonafide® Health Announces Expansion to Retail with Exclusive Launch into 1,800+ Target Stores and Target.com

New York, NY, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Bonafide Health, LLC, a leading direct-to-consumer women’s healthcare company that provides clinically researched solutions to effectively relieve...